MedTrace Logo

Dose Related Effects of Radial Extracorporeal Shock Wave Therapy on Upper Trapezius Trigger Points in Patients With Cervicogenic Headache.

NCT06879418 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2025-11-18

No results posted yet for this study

Summary

A randomized double blinded controlled trial will be conducted to determine and compare the effects of low and medium dose radial extracorporeal shock wave therapy on upper trapezius trigger points in patients with cervicogenic headache. Data will be collected at base line and at the end of the treatment program. Participants will be assigned randomly into three groups Group (A) will receive 2000 shock waves at frequency 10 MHz and 0.045 mj/mm2 flux density plus strengthening and stretching exercise for upper trapezius muscle.

Group (B) will receive 2000 shock waves at frequency 10 MHz and 0.18 mj/mm2 energy flux density plus strengthening and stretching exercise for upper trapezius muscle.

Group (C) will receive sham shock wave therapy plus strengthening and stretching exercise for upper trapezius muscle.

Conditions

  • Cervicogenic Headache

Interventions

OTHER

Low dose shock wave therapy plus strengthening and stretching exercise for upper trapezius

Patients will receive 2000 shocks, 1 bar (energy flux density 0.045 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching exercises for upper trapezius.

OTHER

Medium dose shock wave therapy plus strengthening and stretching exercise for upper trapezius

patients will receive 2000 shock with 4 bars (Energy flux density 0.18 mj/mm2) at frequency 10 MHz on upper trapezius trigger points plus strengthening and stretching for upper trapezius

OTHER

sham shock wave therapy plus strengthening and stretching exercise for upper trapezius

patients will receive 2000 shock with energy flus density 0.00 on upper trapezius trigger points plus strengthening and stretching exercise for upper trapezius.

Sponsors & Collaborators

  • MTI University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-08-30
Completion
2025-09-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879418 on ClinicalTrials.gov